Suppression of allograft rejection is central to successful organ transplantation; thus,
immunosuppressive agents are crucial for successful allograft function. Immunosuppressive …

The aim of this review is to analyse critically the recent literature on the clinical
pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients …

Individual variability in drug efficacy and drug safety is a major challenge in current clinical
practice, drug development, and drug regulation. For more than 5 decades, studies of …

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

The calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant
drugs used for the prevention of organ rejection following transplantation. Both agents are …

In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most
recent advances in the drug/dose optimization of TAC taking into account specific clinical …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …